Bayesian Capital Management LP Makes New Investment in Vir Biotechnology, Inc. (NASDAQ:VIR)

Bayesian Capital Management LP bought a new position in Vir Biotechnology, Inc. (NASDAQ:VIR) during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 25,600 shares of the company’s stock, valued at approximately $259,000.

A number of other institutional investors have also added to or reduced their stakes in the business. Vanguard Group Inc. increased its stake in Vir Biotechnology by 0.6% in the 1st quarter. Vanguard Group Inc. now owns 12,375,355 shares of the company’s stock worth $125,362,000 after acquiring an additional 78,216 shares during the last quarter. Charles Schwab Investment Management Inc. increased its position in shares of Vir Biotechnology by 4.4% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 753,073 shares of the company’s stock valued at $7,576,000 after purchasing an additional 31,405 shares during the last quarter. Empowered Funds LLC increased its position in shares of Vir Biotechnology by 8.2% during the 1st quarter. Empowered Funds LLC now owns 458,044 shares of the company’s stock valued at $4,640,000 after purchasing an additional 34,640 shares during the last quarter. Corient Private Wealth LLC increased its position in shares of Vir Biotechnology by 11.3% during the 4th quarter. Corient Private Wealth LLC now owns 267,279 shares of the company’s stock valued at $2,689,000 after purchasing an additional 27,115 shares during the last quarter. Finally, Nordea Investment Management AB increased its position in shares of Vir Biotechnology by 58.7% during the 1st quarter. Nordea Investment Management AB now owns 235,664 shares of the company’s stock valued at $2,408,000 after purchasing an additional 87,190 shares during the last quarter. 65.32% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several brokerages have recently commented on VIR. Needham & Company LLC increased their price objective on Vir Biotechnology from $15.00 to $19.00 and gave the company a “buy” rating in a research report on Wednesday, June 5th. HC Wainwright reiterated a “buy” rating and set a $110.00 price objective on shares of Vir Biotechnology in a research report on Wednesday, June 5th. JPMorgan Chase & Co. raised their price target on Vir Biotechnology from $10.00 to $12.00 and gave the stock a “neutral” rating in a research report on Friday, May 3rd. Finally, Morgan Stanley raised their price target on Vir Biotechnology from $12.00 to $15.00 and gave the stock an “equal weight” rating in a research report on Thursday, June 6th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $34.00.

Insider Activity

In other Vir Biotechnology news, Director Saira Ramasastry sold 4,000 shares of Vir Biotechnology stock in a transaction on Tuesday, June 11th. The stock was sold at an average price of $10.95, for a total transaction of $43,800.00. Following the completion of the transaction, the director now owns 14,619 shares in the company, valued at $160,078.05. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 15.60% of the stock is currently owned by company insiders.

Vir Biotechnology Stock Up 0.2 %

VIR opened at $10.16 on Thursday. The stock has a market cap of $1.38 billion, a PE ratio of -2.53 and a beta of 0.48. The business has a 50 day moving average of $9.88 and a 200-day moving average of $9.82. Vir Biotechnology, Inc. has a 52 week low of $7.61 and a 52 week high of $14.27.

Vir Biotechnology (NASDAQ:VIR) last released its earnings results on Thursday, May 2nd. The company reported ($0.48) EPS for the quarter, beating analysts’ consensus estimates of ($0.99) by $0.51. The company had revenue of $56.38 million during the quarter, compared to analysts’ expectations of $11.71 million. Vir Biotechnology had a negative return on equity of 32.58% and a negative net margin of 677.69%. The firm’s revenue for the quarter was down 10.5% compared to the same quarter last year. During the same quarter last year, the business posted ($1.06) EPS. Equities analysts anticipate that Vir Biotechnology, Inc. will post -3.57 EPS for the current year.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It offers tobevibart + elebsiran for the treatment of chronic hepatitis delta; elebsiran + PEG-IFN-a, tobevibart ± elebsiran ± PEG-IFN-a, and elebsiran+ TLR8+PD-1 for the treatment of chronic hepatitis B; VIR-1388 and Cure mAb combination for the treatment of human immunodeficiency virus; VIR-8190 for the treatment of respiratory syncytial virus / human metapneumovirus; VIR-2981 for the treatment of influenza; VIR-1949 for the treatment of pre-cancerous HPV lesions; and VIR07229 and Sotrovimab for the treatment of COVID-19 infection under the Xevudy brand.